Living Biohybrid Hydrogels for Co‐Delivery of Oxygen, Anti‐Cancer Drugs, and Probiotics: Effects on Cancer and Healthy Cell Viability Authors: Ulvi Süleymanzade, Tugba Ezgi Şahin, Yagmur Damla Demir, Yagmur Eylül Yatar, Nermin Seda Kehr Published: 2026 ABSTRACT ABSTRACTIn recent studies, oxygen (O2) delivery biomaterials have been developed to reduce hypoxia‐induced problems in, e.g., tumor tissues. However, none of these studies have used inhibitory effects of probiotics in combination therapies with O2 and anticancer drugs for advanced cancer treatment applications. In this study, we report a new probiotic‐enriched 3D‐printed biomaterial (3D‐BioHybrid‐DOX/SPEP) that is capable of O2, probiotic, and acidic pH (pH 6.0) sensitive anticancer drug (Doxorubicin = DOX) co‐release. 3D‐BioHybrid‐DOX/SPEP shows sustained O2 and pH‐responsive anticancer drug release over 14 days. The release of short‐chain fatty acids, including butyric acid, was detected on days 1 and 7 of incubation, indicating that the O2 delivery component of the system supports probiotic viability while mitigating the toxic effects of DOX. The CFU results show that the 3D‐BioHybrid‐DOX/SPEP supports probiotic viability at 1 and 7 days of incubation. In vitro cell experiments indicate that the healthy cell viability is ca. 2 times higher than cancer cells after 1 and 7 days of incubation at hypoxia conditions in 3D‐BioHybrid‐DOX/SPEP due to the co‐administration of O2, DOX, and probiotics.Keywords: biohybrid hydrogels, hypoxia, pH‐responsive delivery, probiotics Introduction Cancer is a global health problem affecting countries all over the world [1]. Different traditional and commonly used therapeutic modalities are available to treat and manage cancer, including surgery, radiation therapy and chemotherapy [2, 3]. Some of the modern modalities include hormone‐based therapy, anti‐angiogenic methods, stem cell therapies, targeted therapy with nanoparticles, probiotics and dendritic cell‐based immunotherapy. Since cancer is a very complex set of disease conditions that progresses gradually, combinatorial strategies involving multiple therapies have been found to have a synergistic effect [4]. However, most of both traditional and modern methods or combinatorial strategies do not consider the impact of hypoxia and subsequent chronic inflammation on cancer tissue development and metastasis. Insufficient and uneven oxygen (O2) distribution in tissues leads to hypoxic conditions and hence cell apoptosis, tissue necrosis, and impaired tissue healing [5]. Hypoxia is a defining feature of solid tumors because tumor tissue tends to have a leaky and abnormal vasculature and rapidly proliferating cancer cells, resulting in low O2 levels. O2 deprivation affects the signaling and biological activity of cancer cells and prevents the effectiveness of anticancer drugs on the tumor. This makes it easier for cancer cells to migrate and tumors to metastasize [6]. Therefore, O2 supplementation in cancer therapy reinforces the efficacy of antitumor drugs on tumor cells. Furthermore, low O2 levels activate hypoxia‐inducible factors (HIFs) that promote the metastatic potential of tumor cells. In O2‐rich environments, HIFs are degraded via the ubiquitin‐proteasome pathway but stabilize under hypoxic conditions. Hypoxia therefore contributes significantly to the development of tumor metastasis and chemotherapy resistance [7]. On the other hand, hypoxic cells rely on anaerobic glycolysis, which leads to the accumulation of lactic acid and thus to a lower pH. Therefore, surrounding tumor tissue and inflamed tissues, regions of hypoxia often have lower than average pH values (pH 6.0–7.0) [8, 9, 10]. In recent methods [5, 11, 12, 13, 14], biomaterials have been developed that can provide controlled, sufficient, and prolonged O2 to support tissues under hypoxic conditions until vascularization is complete (at least 1 week) [15]. Different O2 sources have been used in the development of these biomaterials. The most commonly used O2 sources are solid inorganic peroxides [e.g., calcium peroxide (CaO2), sodium percarbonate (Na2CO3.3H2O2), and manganese dioxide (MnO2)], liquid peroxides [hydrogen peroxide (H2O2)], algae, and perfluorocarbons (PFCs) [5, 16, 17, 18]. O2 sources are often encapsulated in polymer microspheres or adsorbed onto films, fibers, and three‐dimensional (3D) scaffolds, allowing their controlled release. However, very few studies in this field have used O2‐releasing biomaterials alone or in combination with anti‐cancer drugs for cancer treatment [19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30]. For example, a manganese dioxide nanoparticle (MnO2 NP)‐based system for tumor photodynamic therapy was reported. The results showed that significant tumor growth inhibition was observed in the MnO2 NP‐treated group after laser irradiation. This demonstrates the ability of MnO2 NP to generate O2 useful for photodynamic cancer therapy [19]. Another contribution described a microbubble system containing O2‐filled PFC gas to overcome tumor hypoxia. Although preliminary in vivo results have shown the system to be a potentially effective platform for non‐invasive delivery, a sudden release of O2 was observed within the first 20 minutes. This can be toxic to healthy cells and tissues [20]. Another contributor developed a site‐specific O2 source composed of CaO2 and alginate to enhance the cytotoxicity of anticancer drugs in malignant tissues. In this study, an O2‐generating system allowing regional O2 therapy was used in combination with an anticancer drug, doxorubicin (DOX). The results show that the cytotoxicity of DOX is enhanced under normoxic/hypoxic conditions, which in turn induces cancer cell death [21]. In different studies, perfluorohexane‐based nanoparticles were designed to improve the impact of radiotherapy [24] or photodynamic therapy [25] on tumors via applying O2 delivery materials for tumor therapy. We also reported different O2 delivery systems tested on both cancer and healthy cells under hypoxic and normoxic conditions [27, 28, 29, 30]. In one of the most recent studies of us, we prepared a nanocomposite hydrogel consisting of pH‐responsive O2 and anticancer drug (DOX) carrying nanomaterials. These nanomaterials incorporated hydrogel promoted a decrease in the viability of cancer cells than healthy cells by providing sustained O2 and pH‐sensitive anticancer drug release but failed to inhibit cancer cell proliferation under both hypoxic and normoxic conditions. Besides drug delivery applications such as smart hydrogel‐based platforms [31, 32], some studies have shown that probiotics may help immunomodulation of the beneficial bacteria involved in cancer prevention and treatment [33]. Probiotics can regulate the production of antitumor metabolites, including pyridoxine and short‐chain fatty acids (SCFA) [34] such as butyric acid, which promote acidosis and apoptosis of cancer cells and anti‐inflammatory cytokines [35], and can also inhibit the production of harmful carcinogenic compound‐producing enzymes by reducing degradative bacteria in the gut [36]. Probiotic metabolites such as SCFAs (e.g., acetic acid, butyric acid, propionic acid, valeric acid) enable the binding and degradation of carcinogenic compounds and the activation of anti‐inflammatory cytokines [37, 38]. All these functions affect tumor cell proliferation and death, thereby preventing/suppressing carcinogenesis [39]. Therefore, probiotics are used in combination therapies where radiation, chemo and immunotherapy are used in conventional cancer treatments [40, 41]. The inhibitory effects of probiotics have been demonstrated on human lung, colon, stomach, breast and bone cancer cells [42, 43]. Furthermore, some probiotics selectively localize and proliferate in anaerobic environments, such as in solid tumors, but not in healthy organs such as liver, spleen, kidney, lung, blood, bone marrow, and muscle [44]. Although probiotics have several benefits for cancer therapy, the efficacy of probiotics is limited under harsh conditions such as temperature, pH, enzymatic attack and the presence of cytotoxic chemicals (e.g. antibiotics and anticancer drugs). Therefore, some studies have encapsulated microorganisms (probiotics and bacteria) in hydrogels, polymers or silica to enhance their viability and biological functions [45, 46, 47]. Alginate, gellan gum, xanthan gum, Κ ‐carrageenan, chitosan, gelatin and silica have been used for encapsulation due to their non‐toxicity, biocompatibility and low cost. For example, encapsulation and layer‐by‐layer techniques have been used to enhance and protect the bioactivity of probiotics or other bacteria. Sakkos et al. used the layer‐by‐layer technique to enhance biocatalyst activity and protect the biocatalyst against stress factors. Escherichia coli (E. coli) was used as a model biocatalyst and coated with up to ten layers of poly(diallyldimethylammonium chloride) and silica [48]. Wang et al. used mucoadhesive chitosan (CS) and immunomodulatory hyaluronic acid (HA) to coat probiotics by a double‐layer electrostatic assembly technique. The coated probiotics showed enhanced bioactivity, suppressed inflammation, and remodeled the gut microenvironment [49]. In another study, Wang et al. reported polydopamine nanocoated bacteria showing high catalytic activity and reusability [50]. A silica gel encapsulation method based on sol‐gel migration of a silicon alkoxide or silica nanoparticles to coat the bacterial surface has also been applied to maintain the catalytic activity of encapsulated organisms [51, 52]. Mutlu et al. reported silicon alkoxide cross‐linked silica gels for encapsulation of bacterial biocatalysts and reported that these gels retained high biocatalytic activity and were applied to remove trace levels of atrazine with high removal efficiency for at least two months [51]. Haffmer et al. described the encapsulation of Lactobacillus rhamnosus GG in alginate‐mesoporous silica microcapsules with a core shell, allowing nutrient‐metabolite diffusion and bacterial growth inside these capsules [52]. Probiotics were also encapsulated in alginate. Thus, antibiotic exposure did not affect the growth and metabolic activity of probiotics and allowed diffusion of probiotic by‐products [53]. Zheng et al. reported that probiotic spores encapsulated with prebiotics inhibited tumor growth in colon cancer by 89% and up to 65% due to the production of anti‐cancer SCFAs [54]. Recently, Wang et al. reported that co‐administration of starch‐encapsulated probiotics with a chemotherapy agent suppressed colon tumor growth due to regulation of inflammation and chemotherapy‐induced microbial dysbiosis [55]. Despite the known beneficial effects of probiotics, protected probiotics have not been used in combination therapies with O2 and anticancer drugs for advanced cancer therapy applications. Therefore, in this study, we report a novel multifunctional probiotic‐enriched biomaterial, i.e., “BioHybrid Hydrogel.” Our new biomaterial consists of O2‐carrying reagents homogeneously and covalently bound in a hydrogel network, nanomaterials capable of O2 and anticancer drug delivery, and probiotics producing anticancer and anti‐inflammatory metabolites protected by organosilica nanoparticles and polymer. This biomaterial has the ability to co‐release O2, probiotic metabolites, and acidic pH (pH 6.0) sensitive anticancer drugs and therefore has the potential to promote improved minimally invasive multidrug therapy applications with cancer cells under hypoxic conditions. Results Protection of Probiotics With Organosilica Nanoparticles and Polymer Probiotics are very sensitive to environmental factors that limit their beneficial effects. Therefore, to protect probiotics [e.g. Lactobacillus casei (L. casei)] from environmental factors such as temperature, pH changes, chemicals, etc. [56, 57], we engineered them with organosilica nanoparticles and polymer‐based coatings. Probiotics were first interacted with periodic mesoporous organosilica (PMO‐NH2) nanoparticles functionalized with a positively charged amino‐group, then with negatively charged alginate (Alg) polymer, and finally with positively charged PMO‐NH2. We also loaded the PMO‐NH2 nanomaterials with Lactose (Lac) to provide nutrients to probiotics and increase their viability. PMO‐NH2 was synthesized and loaded with Lactose to get LacPMO‐NH2 according to the modified literature procedure [35]. The synthesized PMO‐NH2 and LacPMO‐NH2 were characterized using SEM (Figure 1A,B), dynamic light scattering (DLS) and zeta potential (Table S1, Supporting Information). SEM showed that PMO‐NH2 and LacPMO‐NH2 have a spherical morphology. The average diameter of PMO‐NH2 and LacPMO‐NH2 was shown to be 177.8 ± 0.9 nm and 183.4 ± 5.1 nm by DLS. The zeta potential of PMO‐NH2 changed from 26.9 ± 1.5 to 7.3 ± 8.9, indicating the incorporation of negatively charged Lac on the PMO‐NH2 surface. SEM image of PMO‐NH2 (A) and LacPMO‐NH2 (B). Lactose release from LacPMO‐NH2 (C). Analysis of live/dead staining test results of probiotics coated with different ratios of LacPMO‐NH2 (D,G), LacPMO‐NH2 /Alg (E,H), LacPMO‐NH2 /Alg/ LacPMO‐NH2 (F,I) (0.3, 0.5, and 1 mg/mL) (Ex: 485/535 nm, Em: 560/612 nm) after 1 and 7 days by microplate reader. Em: Fluorescence intensity at 535 nm indicates the proportion of live probiotics (D–F). Em: Fluorescence intensity at 612 nm indicates the proportion of dead probiotics (G–I). The impact of LacPMO‐NH2, LacPMO‐NH2 / Alg, and LacPMO‐NH2 / Alg / LacPMO‐NH2 on the viability of probiotics determined by CFU analysis (J). The impact of LacPMO‐NH2 and PMO‐NH2 on the viability of probiotics determined by CFU analysis (K) (control sample refers to the non‐coated probiotics). (N = 3; *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA). The SEM images of probiotic clusters (L), LacPMO‐NH2 coated probiotic clusters (M), LacPMO‐NH2 / Alg coated probiotic clusters (N), LacPMO‐NH2 / Alg / LacPMO‐NH2 coated probiotic clusters (O). Lactose absorbed and released from the LacPMO‐NH2 surface was determined by UV‐Vis spectrometry. It was found that 71% of Lac was adsorbed on LacPMO‐NH2. 38% and 0% of the adsorbed Lac was released from LacPMO‐NH2 at pH 6.0 and pH 7.4 over a period of 7 days (Figure 1C). The release behavior is more plausibly governed by changes in the surface charge of the nanoparticle carriers. Variations in pH can alter the protonation state and surface charge density of the carrier, thereby affecting its interaction with lactose. As lactose is expected to interact with the carrier primarily through hydrogen bonding, any weakening or rearrangement of these interactions at pH 6.0 may facilitate its release. Then, in a stepwise and layer‐by‐layer approach, the probiotics were mixed with LacPMO‐NH2 for the 1st coating, Alg for the 2nd coating, and LacPMO‐NH2 for the 3rd coating to increase the viability of the probiotics. A live/dead staining experiment was performed to find the optimum concentration of LacPMO‐NH2 / Alg / LacPMO‐NH2 on the viability of the probiotic (Figure 1D–I). In the first step, probiotics (1 × 105 CFU/mL) and different ratios of LacPMO‐NH2 (0, 0.3, 0.5, and 1 mg/mL LacPMO‐NH2) were mixed in PBS at 37 °C for 1 and 7 days. After 1 and 7 days of incubation, probiotic viability was determined by a live/dead staining test with a microplate reader (Ex: 485/535 nm, Em: 560/612 nm) (Figure 1D,G). The results showed that 1.0 mg/mL LacPMO‐NH2 reached the highest fluorescence intensity at 535 nm (indicating the proportion of live probiotics) (Figure 1D). Furthermore, the fluorescence intensity at 612 nm (indicating the proportion of dead probiotics) on days 1 and 7 was not different from the control sample (probiotics containing 0 mg/mL LacPMO‐NH2) (Figure 1G). These results indicated that 1 mg/mL LacPMO‐NH2 was the best concentration that could provide higher probiotic viability compared to the control sample. In the next step, the best probiotic / LacPMO‐NH2 ratio was used in the coating step with the polyanionic polymer Alg. In this stage, probiotic / LacPMO‐NH2 was mixed with different ratios of Alg (0, 0.3, 0.5, and 1 mg/mL Alg) in PBS for 1 and 7 days. The viability test of probiotics was performed according to the procedure described above for LacPMO‐NH2. The results showed that coating probiotics with Alg was not very effective in increasing the viability of probiotics depending on the Alg concentration. The fluorescence intensity at 535 nm (indicating the proportion of live probiotics) (Figure 1E) and 612 nm (indicating the proportion of dead probiotics) (Figure 1H) did not change much on days 1 and 7 compared to the control group (group containing 0 mg/mL Alg), indicating that coating probiotics with Alg does not have much effect on probiotic viability. In the final step, the best probiotic / LacPMO‐NH2 / Alg ratio was used in the 3rd coating step with LacPMO‐NH2. In this step, probiotics / LacPMO‐NH2 / Alg were mixed with different ratios of LacPMO‐NH2 (0, 0.3, 0.5, and 1 mg/mL LacPMO‐NH2) in PBS for 1 and 7 days. The viability test of the probiotics was performed according to the procedure described above for LacPMO‐NH2. The results showed that coating probiotics with LacPMO‐NH2 increased the viability of probiotics depending on the concentration of LacPMO‐NH2. The fluorescence intensity increased at 535 nm (indicating the proportion of live probiotics) (Figure 1F), while at 612 nm (indicating the proportion of dead probiotics) (Figure 1I), it did not change on days 1 and 7 compared to the control group (group containing 0 mg/ml LacPMO‐NH2). This indicates that coating probiotics with LacPMO‐NH2 for the 3rd time increased the probiotic viability again. Furthermore, colony‐forming unit (CFU) analysis was performed to prove the beneficial effect of LacPMO‐NH2 / Alg / LacPMO‐NH2 coating on the viability of probiotics (Figure 1J,K). The results showed that the 1st coating (only with LacPMO‐NH2) reduced the viability of probiotics compared to control sample (non‐coated probiotics), showing that 1st coating has a toxic effect on the viability. The reason can be attributed to the positively charged LacPMO‐NH2 surface induced permeabilization in the negatively charged membrane of probiotics. On the other hand, 2nd (coating with LacPMO‐NH2 / Alg) and 3rd (coating with LacPMO‐NH2 /Alg / LacPMO‐NH2) coatings significantly improved the viability of probiotics (Figure 1J). The CFU was also done when probiotics were interacted with PMO‐NH2 and LacPMO‐NH2 to show the beneficial effect of Lac in the PMO‐NH2 (Figure 1K). Our results show that LacPMO‐NH2 caused higher probiotic viability than PMO‐NH2. That was most probably due to the positively charged PMO‐NH2 generated toxic effect via inducing the permeabilization in the negatively charged membrane of probiotics. On the other hand, Lac on the LacPMO‐NH2 created a less positively charged surface and provided sustained nutrition release, which reduced the toxic effect of LacPMO‐NH2 and improved the viability of probiotics. The size of the probiotic was increased with each coating and reached 2755 ± 1623 nm after the 3rd coating (Table S2, Supporting Information; Figure S1, Supporting Information). Moreover, the zeta potential shifted from −10.5 ± 0.4 mV to −0.4 ± 0.1 mV after coating with LacPMO‐NH2, consistent with the presence of the positively charged LacPMO‐NH2 coating. The 2nd coating with negatively charged alginate shifted the zeta potential to −14.3 ± 0.1 mV. After the 3rd LacPMO‐NH2 coating, the zeta potential increased to −4.9 ± 0.3 mV but remained negative, suggesting that the positively charged outer LacPMO‐NH2 layer partially compensated for the negative surface charge introduced by the alginate layer. The size of the probiotics coated with LacPMO‐NH2 and Alg increased with each coating. SEM images showed that the probiotics were cylindrical and formed clusters (Figure 1L). Figure 1M shows the LacPMO‐NH2 nanoparticles on the probiotic colonies. The adjacent hills indicate probiotic clusters coated with LacPMO‐NH2 nanoparticles. In Figure 1N, these hills are more prominent, but the prominence of LacPMO‐NH2 nanoparticles is reduced, indicating that they were covered with Alg. In Figure 1O, the LacPMO‐NH2 nanoparticles were again prominent above the hills, indicating the third coating. We have marked some of the spots with a red arrow, which we consider to be significant. Synthesis of Oxygen Delivery Hydrogel In this study, we used gelatin‐based hydrogels because of their good cell adhesion properties due to the Arg‐Gly‐Asp (RGD) sequences of gelatin. Gelatin‐based polymers such as gelatin‐methacryloyl (GelMA) [58] form hydrogels through photo‐crosslinking via covalent bonds. Furthermore, the mechanical strength, toughness, and injectability of GelMA can be improved by incorporating naturally derived non‐toxic and non‐immunogenic polymers such as Alg and/or nanomaterials into the hydrogel polymeric network. GelMA was synthesized according to the procedure in the literature [29]. The degree of methacrylation of gelatin was about 71%. The successful grafting of methacryloyl groups was qualitatively confirmed by the appearance of the characteristic double‐bond peak at δ 5.4–5.7 ppm in the 1H NMR spectrum (Figure S2B, Supporting Information). The synthesized GelMA was further modified with PFCs to obtain O2‐carrying polymer (GelMAF) due to the high O2‐adsorption capacity and useful properties of PFCs in biomedical uses. PFCs can dissolve 20 times more O2 than O2 solubility in water. This is explained by Van der Waals interactions between a large number of fluorines and O2 [59]. For this reason, PFCs have been approved by the Food and Drug Administration (FDA) for use in oxygenating blood during certain surgical procedures [60]. PFCs have also been used as O2 suppliers for tissue engineering applications due to their ability to dissolve large amounts of O2 and release it when the O2 content in the environment decreases. Therefore, the mechanism of O2 delivery is based on the diffusion of O2 from concentrated O2 in the PFC to a lower hypoxia environment [61]. The synthesized GelMAF was characterized with 1H‐ and 19F‐NMR (Figure S2C,D, Supporting Information). The 1H‐NMR showed that the degree of functionalization of GelMA (Figure S2C, Supporting Information) was 51%. The observed F peaks in the 19F‐NMR spectrum confirmed the functionalization of GelMA with pentadecafluorooctanoyl chloride (Figure S2D, Supporting Information). Generation and Characterization of BioHybrid Hydrogels We used pH‐responsive, O2, and drug‐carrying periodic mesoporous organosilica (PMO) nanomaterials (DOXPMOF‐P). DOXPMOF‐P was previously synthesized by us [30]. Briefly, PMO nanomaterials were conjugated with PFCs, loaded with anticancer drug (DOX) molecules and coated with poly‐D‐lysin (PDL) to obtain DOXPMOF‐P. The DLS and zeta potential of previously synthesized DOXPMOF‐P (Table S3, Supporting Information) were measured before use and found to be in agreement with previous results [29]. The prepared GelMAF was mixed with Alg or with DOXPMOF‐P and Alg to obtain the GelMAF/Alg (GA) and the nanocomposite hydrogel GelMAF/Alg‐DOXPMOF‐P (GA‐DOXPMOF‐P). The prepared organosilica/polymer encapsulated probiotics (LacPMO‐NH2 / Alg / LacPMO‐NH2 coated probiotics = SPEP) were then incorporated into GA‐DOXPMOF‐P to form ‘BioHybrid Hydrogels’ namely GA‐DOXPMOF‐P/SPEP (BioHybrid‐DOX/SPEP). Furthermore, a BioHybrid hydrogel without DOXPMOF‐P, consisting only of encapsulated probiotics and GelMAF‐Alg (GA) (BioHybrid‐SPEP) was prepared as well for further experiments. The rheological and mechanical properties of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP were characterized (Figure 2). Complex viscosity curves and storage modulus (G′) and loss modulus (G′′) as a function of angular frequency were analyzed. The results showed that complex viscosity decreases with increasing angular frequency (Figure 2A). The significant decrease in complex viscosity due to the incorporation of SPEP into the hydrogel may be due to the disruption of the homogeneous interaction of GelMAF and Alg in the GA network. On the other hand, the incorporation of DOXPMOF‐P into the GA network increased the complex viscosity values for both GA‐DOXPMOF‐P and BioHybrid‐DOX/SPEP, especially at low angular frequencies, indicating that the homogeneous diffusion of DOXPMOF‐P within the GA network leads to an additional interaction between DOXPMOF‐P and GelMAF and Alg. The large surface area of the positively charged DOXPMOF‐P interacted electrostatically with the negatively charged parts of the GA, and this interaction enhanced the properties of the GA network. The addition of SPEP to the hydrogel also reduced the storage modulus (G′) and loss modulus (G′′) in the angular velocity range, but this was improved by the addition of DOXPMOF‐P to the GA network. GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP showed higher storage modulus (G′) than loss modulus (G′′) in the angular velocity range, indicating that all samples have viscoelastic properties (Figure 2B). This means that when DOXPMOF‐P increased the network density, leading to higher complex viscosity and storage modulus, SPEP acted as a softening additive that disrupted the polymer network, resulting in a decrease in rheological strength. Complex viscosity (A) and storage modulus (G′) and loss modulus (G″) (B) of the GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP and BioHybrid‐DOX/SPEP as a function of angular frequency. Tensile stress‐strain curves (C) and compressive modulus (D) of the GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP and BioHybrid‐DOX/SPEP (10 N). (N = 3; *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA). Mechanical tests were then performed on GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP. The inclusion of DOXPMOF‐P improved the mechanical properties of GA and BioHybrid‐SPEP, while SPEP decreased the mechanical properties of GA. These results showed that the homogeneous distribution of DOXPMOF‐P generated extra strength against the applied force, thus improving the stress‐strain ratio (Figure 2C) and compressive modulus (Figure 2D). However, SPEP caused higher strain but lower stress, resulting in a softer but stretchable network. In addition, SPEP led to a decrease in compression modulus of BioHybrid‐SPEP due to the disruption of the homogeneous interaction of GelMAF and Alg, as shown by the complex viscosity and rheological data. Interestingly, however, the highest stress‐strain ratio and compressive modulus were obtained in BioHybrid‐DOX/SPEP, which contains both DOXPMOF‐P and SPEP. This result indicates that a stronger network structure forms in the hydrogel matrix in the presence of DOXPMOF‐P and SPEP. While DOXPMOF‐P alone enhances mechanical strength, SPEP, which has a softer structure, facilitates stress redistribution. This dual effect reduces stress concentration and delays structural failure under load. As a result, although the hybrid system exhibits lower rheological stiffness compared to the group containing only nanoparticles, it demonstrates higher resistance to applied stress and the highest compressive modulus due to improved toughness and reduced brittleness. 3D Printing of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP and Their Characterization BioHybrid‐DOX/SPEP was first printed at 40%, 60%, and 90% filler density (Figure 3A–I), and 3D‐BioHybrid‐DOX/SPEP was obtained to find the optimum porosity of the 3D scaffolds. The results showed that BioHybrid‐DOX/SPEP can be easily printed with a 3D printer, and although they retained their shape properties, SEM images showed some closure of the pores after freeze‐drying. Post‐printing (A–C), optical microscope (D–F), and SEM (G–I) images of 3D‐BioHybrid‐DOX/SPEP printed at 40% (A, D, G), 60% (B, E, H), and 90% (C, F, I) infill densities. Degradation graph of 3D‐BioHybrid‐DOX/SPEP printed at 40%, 60%, and 90% infill densities after 1 and 7 days of incubation (J). Cell viability (Optical density = OD at 450 nm) graphs of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP samples printed at 40%, 60%, and 90% infill densities after 1 (K) and 7 (L) days of incubation in media. SEM images of 3D‐GA (M), 3D‐GA‐DOXPMOF‐P (N), 3D‐BioHybrid‐SPEP (O), and 3D‐BioHybrid‐DOX/SPEP (P). Images of 3D‐GA (Q), 3D‐GA‐DOXPMOF‐P (R), 3D‐BioHybrid‐SPEP (S), and 3D‐BioHybrid‐DOX/SPEP (T) immediately after 3D printing. (N = 3; *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA). First, degradation tests (Figure 3J) were performed to find the porosity that provides the highest durability for 3D‐BioHybrid‐DOX/SPEP printed with 40%, 60%, and 90% filler densities. The results revealed that 90% filler density showed less degradation than the other ratios, especially after 1 day of incubation, and 40% and 60% filler densities showed almost the same degradation rate. Thereafter, cell viability testing was also performed for all samples to find the best porosity ratio that gave the highest cell viability (Figure 3K,L). The cell viability test showed that at the end of 1 day and 7 days of incubation, each of the samples printed at 90% fill density resulted in higher cell viability than the samples printed at 40% and 60% fill density. This difference was particularly evident on day 1, and cell viability was further increased in the presence of SPEP and O2‐conducting PMOF. As a result of this optimization, the other experiments were performed only with 3D scaffolds printed at 90% fill density. The other samples, 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP were 3D printed at 90% filler density, freeze‐dried, and SEM images were taken (Figure 3M–T). In the next step, the porosity, swelling, and degradation properties of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP hydrogels and their O2, DOX, and metabolite release properties were determined. The ethanol replacement method was used for porosity (porosity %) measurements of the entire hydrogel volume. The fact that 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP have nearly identical porosities indicates that SPEP and DOXPMOF‐P do not cause a significant change in porosity. These results show that DOXPMOF‐P and SPEP do not alter the overall porosity of the hydrogel and that all samples have high porosity (Figure 4A; Table S4, Supporting Information). DOXPMOF‐P and SPEP increased the swelling rate of 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP (Figure 4B). The hydrophilic DOXPMOF‐P and LacPMO‐NH2 in the structure of SPEP improved the swelling properties of the hydrogel by increasing its water‐holding capacity. On the other hand, the addition of DOXPMOF‐P to GA was observed to reduce the degradation of 3D‐GA‐DOXPMOF‐P and 3D‐BioHybrid‐DOX/SPEP (Figure 4C). This is attributed to the increased mechanical strength of hydrogels in the literature. However, the addition of SPEP decreases the mechanical properties of the hydrogel and leads to increased degradation as observed in mechanical tests. The weight loss (%) of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP was higher in the presence of cells, indicating cell‐mediated biodegradation of the BioHybrids (Figure 4D). Porosity (A) and swelling (B) properties of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP. Degradation properties of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP in the absence (C) and in the presence of cells (D). DOX release from 3D‐GA‐DOXPMOF‐P and 3D‐BioHybrid‐DOX/SPEP at pH 6.0 and pH 7.4 (E). Determination of probiotic viability in 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP at pH 6.0 and 7.4 after 1 (F) and 7 days (G) by the CFU method (control sample refers to the non‐coated probiotics). O2 release at normoxic (H) and hypoxic (I) conditions (control refers to the 3D‐GelMA‐Alg in cell culture medium). (N = 3; *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA). The crosslink densities of the hydrogel samples were calculated according to the Flory‐Rehner equation, as in the literature [62]. The results indicate a strong correlation between hydrogel crosslinking density, rheological and mechanical properties, and degradation/swelling behavior (Figure S3, Supporting Information). The addition of nanoparticles increased the storage modulus and cross‐link density while reducing swelling and degradation at full swelling (7 days); this indicates a tightly cross‐linked network resistant to hydrolytic and enzymatic degradation. In contrast, the addition of probiotics increased swelling and accelerated degradation by reducing cross‐linking density and mechanical strength; this is consistent with a softer and less stable network. Overall, these observations highlight the critical role of network reinforcement in controlling the hydrogel's stability and performance. UV‐Vis spectrophotometry was used to quantitatively determine the amount of DOX released at pH 6.0 and pH 7.4 (Figure 4E). First, different concentrations of DOX in PBS were prepared, and a calibration curve was generated. Then, 3D‐GA‐DOXPMOF‐P and 3D‐BioHybrid‐DOX/SPEP were incubated at 37°C in PBS at pH 6.0 and 7.4 for different times to determine the amount of DOX. The % DOX released was determined using the formula of the calibration curve. In addition, the DOX release profile was determined by the Higuchi and Korsmeyer‐Peppas models in the literature (Figure S4, Supporting Information) [66, 67]. The DOX release profile showed a continuous and pH‐dependent release pattern for 7 days. It was observed that the amount of DOX was higher at pH 6.0 than at pH 7.4. This result is due to intermolecular non‐covalent interactions such as hydrogen bonding between DOX and PMOF, PMOF and PDL (electrostatic interactions and Van der Waals attraction). Electrostatic interactions occur between negatively charged PMOF and positively charged DOX and between negatively charged PMOF and positively charged PDL, resulting in a pH‐sensitive system (DOXPMOF‐P). Thus, at pH 6.0 the surface of the negatively charged PMOF can be protonated, resulting in a weaker electrostatic interaction with the positively charged DOX and PDL. Therefore, a higher concentration of DOX release was observed at pH 6.0 compared to pH 7.4. The DOX release profile was compared between the Korsmeyer‐Peppas and Higuchi models, and the R 2 value for each measurement was higher in the Higuchi model. The statistical R 2 ranges from 0 to 1, and the closer it is to 1, the better the model explains the data. The Higuchi model (1) assumes that drug release occurs through a solid matrix and is diffusion controlled, while the Korsmeyer–Peppas model (2) states that drug release depends on multiple factors (e.g. diffusion and swelling of the polymer). Since our system is closer to the Higuchi model due to the size of the R 2 statistical data, we understand that DOX release from the hydrogel medium is more affected by diffusion. M t /M ∞ is the % fractional drug release at time t. K kp and K H are the Kosmeyer–Peppas constant and Higuchi release constant, respectively. n: is a diffusional constant, related to the releasing mechanism. Probiotic metabolites, such as SCFAs released from 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP, were analyzed by HPLC. Metabolite release from uncoated probiotics, LacPMO‐NH2‐coated probiotics, LacPMO‐NH2 / Alg‐coated probiotics, and LacPMO‐NH2 / Alg / LacPMO‐NH2‐coated probiotics (SPEP) were also analyzed for comparison. Calibration curves for acetic acid, propionic acid, and butyric acid were prepared using different concentrations of the respective SCFAs (Figure S5, Supporting Information). The HPLC analysis results (Figure S6, Supporting Information; Table S5, Supporting Information) revealed a significant temporal shift in the SCFA release profile from the probiotics, this profile shifted from a phase dominated by acetic acid on day 1 to a phase dominated by butyric acid by day 7. The most notable results were observed in the 3D‐BioHybrid systems, where encapsulation within the hydrogel was found to fundamentally alter metabolic output. The fact that propionic acid was detected almost exclusively in the 3D‐BioHybrid groups suggests that the 3D scaffold provides a supportive microenvironment that potentially promotes metabolic pathways that remain inactive in simple coatings. Furthermore, the absence of detectable acetic acid combined with a marked increase in butyric acid (particularly in 3D‐BioHybrid‐DOX/SPEP), suggest a metabolic redistribution of carbon flux rather than a selective stimulation of butyrate production. Acetate can be consumed as a co‐substrate for butyrate synthesis [68]. In addition, changes in the microenvironment, including O2 availability, can affect intracellular redox balance and thus alter the distribution of fermentation end products. PMOF‐mediated O2 modulation may play a role in regulating intracellular redox conditions rather than simply increasing O2 availability. Such redox regulation can support metabolic pathways that maintain the NAD+/NADH balance, including those leading to more reduced end products such as butyrate [69, 70]. Additionally, the addition of nanoparticles improves the microenvironment by enhancing structural stability and supports sustainable probiotic activity over time. The presence of DOX may also contribute by inducing metabolic stress or reducing microbial competition, thereby redirecting metabolism toward greater butyrate production. Therefore, the increased butyric acid production observed in the 3D‐BioHybrid‐DOX/SPEP system can be attributed to the combined effects of microenvironment stabilization, redox modulation, and the redistribution of metabolic flux. As a result, while simple coatings provide immediate metabolic activity, 3D‐BioHybrid‐DOX/SPEP can offer a more beneficial SCFA profile. Furthermore, in order to show the viability of probiotics in 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP at pH 6.0 and pH 7.4 were performed CFU analysis. The results revealed that 3D‐BioHybrid‐SPEP exhibited significantly higher viable probiotics than 3D‐BioHybrid‐DOX/SPEP. After incubation for 1 day, we observed that 3D‐BioHybrid‐SPEP increased viability of probiotics ca. 5 and 11 times compared to the control sample at pH 6.0 and pH 7.4 medium (Figure 4F). The 3D‐BioHybrid‐DOX/SPEP failed to sustain probiotic viability at pH 7.4, but it preserved the viability compared to the control sample at pH 6.0. Lac, which is a nutrient for probiotics, was released more at pH 6.0 (25%) than at pH 7.4 (0%) after 1 day (see Figure 1C). This supported the probiotic viability even in the presence of DOX. The absence of Lac release and the release of DOX (12%) at pH 7.4 (Figure 4E) inhibited the probiotics compared to the control sample (Figure 4F). After a 7 days incubation period, we observed that 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP increased viability ca. 16 and 8 times compared to the control sample (non‐coated probiotics) in pH 6.0 medium (Figure 4G). The ability of the 3D‐BioHybrid‐DOX/SPEP to maintain viability at pH 7.4 may be attributed to the O2 unit of DOXPMOF‐P. Overall, the decreased viability of 3D‐BioHybrid‐DOX/SPEP compared to 3D‐BioHybrid‐SPEP may be attributed to the toxic effects of DOX. O2 carrying capacities of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP samples were measured under normoxia (21% O2) and hypoxia (<1% O2) conditions with a fiber optic O2 meter (OXY‐1 SMA) for incubation periods of 1 and 14 days (Figure 4H,I). All samples containing DOXPMOF‐P and GelMAF showed constant O2 content for a long time under normoxia conditions. However, under hypoxia conditions, the O2 content increased in all samples, while in the control sample (3D‐GelMA‐Alg in cell culture medium) the O2 content decreased rapidly and reached the O2 level of the hypoxia medium. In 3D‐BioHybrid‐SPEP, the addition of SPEP increased the O2 content of GA, while in 3D‐GA‐DOXPMOF‐P, the addition of DOXPMOF‐P was more effective in increasing the O2 content. Most importantly, 3D‐BioHybrid‐DOX/SPEP showed the highest O2 content after 14 days of incubation. This is due to the combination of DOXPMOF‐P and SPEP in the same hydrogel. In Vitro Cell Experiments In cell experiments (Figure 5), we used 3D‐printed forms of GelMA‐Alg (control), GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP. GA has O2 transport unit, GA‐DOXPMOF‐P provides O2 and DOX release, BioHybrid‐SPEP has probiotic metabolites and O2 transport unit, and BioHybrid‐DOX/SPEP is the combination of all these samples and provides O2, DOX and probiotic metabolites. GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP and BioHybrid‐DOX/SPEP were mixed with L929 or Malme‐3M cells and 3D printed as cell‐loaded 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP for cell experiments. Cell experiments were performed under normoxic and hypoxic conditions at different time points (1 and 7 days). Healthy mouse fibroblast L929 cells and malignant human melanoma (Malme‐3M) cells were used for cell assays. Data were normalized to the control sample (3D printed form of GelMA‐Alg) for each condition. Cell viability of fibroblast L929 and Malme‐3M cells in the presence of control, 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP after 1 day (A, B) and 7 days (C, D) of incubation under normoxic (A, C) and hypoxic (B, D) conditions. Relative ROS levels of fibroblast L929 and Malme‐3M cells after 1 (E, F) and 7 (G, H) days of incubation under normoxia (E, G) and hypoxia (F, H) in the presence of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP. Data were normalized to the control sample (3D‐printed form of GelMA‐Alg) for each condition. All measurements were performed in triplicate. (N = 3; *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA). We first performed cell viability assays. The WST‐1 assay was used to determine cell viability by spectrophotometric quantification. The results showed that the viability of healthy fibroblast cells was higher than cancer cells in each reaction condition (Figure 5A–D), indicating that O2‐carrying GA and PMOF and probiotic metabolites increased healthy cell viability while decreasing cancer cell viability. These results were more pronounced under hypoxic conditions (Figure 5B,D) compared to normoxic conditions (Figure 5A,C). If we first consider normoxic conditions (Figure 5A,C), we can see that the effect of 3D‐GA‐DOXPMOF‐P and 3D‐BioHybrid‐SPEP, which can provide O2 and metabolites, was more significant on the difference between healthy and cancer cells at 1 day incubation (Figure 5A). However, this difference decreased when 3D‐BioHybrid‐DOX/SPEP was used, although both cell viabilities increased (Figure 5A). This may be due to the different effects of DOX, O2, and metabolites administered together on the cells. While O2 and metabolites increased healthy cell viability, the toxic effect of DOX on cancer cells was masked under this reaction condition. This may be due to the effect of the high concentration of PFC units capable of scavenging reactive oxygen species (ROS) [71], which are associated with the harmful effect of DOX. On the other hand, the difference between healthy and cancer cell viability increased after 7 days of incubation (Figure 5C), indicating that the effect of DOX on cancer cells increased with longer incubation time, which may be due to sustained and pH‐sensitive DOX release over time (see Figure 4E). The large error bars in the 3D‐BioHybrid‐DOX/SPEP group likely reflect biological variability, which may arise from differences in cell responses within the 3D culture system as well as interactions with probiotics included in the experiment. When we considered hypoxia conditions (Figure 5B,D), we observed lower cell viability for 1 and 7 days of incubation compared to normoxia conditions. However, the difference between healthy and cancer cell viability was more pronounced, especially in 3D‐BioHybrid‐DOX/SPEP. Healthy cell viability was approximately 2‐fold higher than cancer cells after 1 day of incubation (Figure 5B). These results showed that even GA hydrogel carrying only O2 was effective in reducing cancer cell viability and this effect was enhanced by 3D‐GA‐DOXPMOF‐P carrying DOX and reached the highest value when the co‐release of O2, DOX and metabolite was achieved by 3D‐BioHybrid‐DOX/SPEP. Although the effect of 3D‐BioHybrid‐SPEP was not high at 1 day of incubation (Figure 5B), its effect after 7 days of incubation (Figure 5D) was remarkable. This result indicated that metabolite release was only affected after longer incubation time in cancer cells. We also observed that healthy cells had higher cell viability than cancer cells in all samples after 7 days of incubation under hypoxia conditions (Figure 5D). The highest effect was seen in 3D‐BioHybrid‐DOX/SPEP due to the co‐administration of O2, DOX, and probiotic metabolite. In summary of the cell viability experiments, these results showed that O2, DOX, metabolites alone and their combination have different effects on healthy and cancer cells, and this is time dependent. GA and PMOF carrying O2 can increase O2 content, which improves the effect of DOX and its detrimental effect on cells [72]. However, this may depend on the concentration of PFC, which may reduce DOX activity through DOX‐mediated scavenging of O2 radicals by PFC. In addition, O2‐carrying samples improved the O2 content of the microenvironment of cells under hypoxia. Therefore, HIFs, which promote cancer cell proliferation under hypoxia conditions, were degraded by O2‐dependent prolyl hydroxylation and ubiquitin‐proteasome pathway in the presence of O2 released from our samples, reducing cancer cell viability [7, 73]. O2 may also affect the metabolic program of cancer cells relying on aerobic glycolysis [74]. On the other hand, O2 promoted aerobic respiration with ATP production via oxidative phosphorylation and increased healthy cell viability under hypoxia conditions by reducing anaerobic stress [75]. The DOX effect was more pronounced at 7 days of incubation under both normoxia and hypoxia conditions due to the sustained release of DOX. DOX intercalates DNA and produces ROS in the presence of O2 [72]. The impact of DOX on healthy cells was minimized by the beneficial effects of O2 on healthy cells [75], while that was improved on cancer cells may be due to higher ROS production under O2‐carrying biomaterials. Probiotic metabolites released from 3D‐BioHybrid‐SPEP showed the highest effect after 7 days of incubation under hypoxia conditions. Probiotic metabolites (e.g. SCFAs) can disrupt cancer cell metabolism and cause apoptosis [76]. However, these metabolites may increase the resistance of healthy cells to oxidative stress [77] and reduce the effect of DOX on their viability. On the other hand, the combined effect of O2, DOX, and 3D‐BioHybrid‐DOX/SPEP metabolites showed the most effective result. O2 can promote probiotic metabolism and increase the activity of DOX, both of which kill cancer cells. O2 and metabolites compensate for the harmful effect of DOX while increasing healthy cell viability. In the short term, the effect of these biomaterials is not very significant, but due to the continuous release of O2, DOX and metabolites, cumulative damage has been observed on cancer cells, while healthy cells mostly remain better off due to probiotic and O2 support. Next, we analyzed the effect of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP on ROS production under both normoxia (Figure 5E,G) and hypoxia (Figure 5F,H) conditions. ROS are products of O2 metabolism in cells under physiological conditions and participate in redox homeostasis and thus in the maintenance of cell signaling, proliferation, and differentiation. However, overproduction of ROS disrupts redox homeostasis, resulting in oxidative stress and ROS‐induced cell damage and diseases [78]. On the other hand, ROS production under hypoxia relies mostly on mitochondrial dysfunctions and hypoxia‐inducible factors (HIFs). Under low O2 conditions, electrons cannot be efficiently transferred to O2 due to low O2 levels. This mitochondrial dysfunction leads to electron leakage, resulting in superoxide formation and activation of HIF‐1α. HIF‐1α promotes ROS production by upregulating different ROS‐producing enzymes such as NADPH oxidase [79]. While ROS is a natural product of healthy cellular metabolism, higher ROS ratios are observed in cancer cells due to the higher rate of proliferation in cancer cells, which results in greater mitochondrial activity and thus greater ROS production [80]. Our results showed that ROS content was higher in cancer cells than in healthy cells in almost all samples. This result suggests that O2, DOX, and probiotic metabolites from 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP individually or in combination cause higher oxidative stress in cancer cells than in healthy cells. On the other hand, the same samples better regulate oxidative stress in healthy cells thanks to O2 and probiotic metabolites; this ability to mitigate the harmful effects of DOX is attributed to the metabolites’ capacity to modulate the cellular response to oxidative stress and promote mitochondrial respiration in the presence of excess O2. The most significant difference between healthy and cancer cells was observed in 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP at 7 days incubation under normoxic conditions (Figure 5G). These results showed that the beneficial effect of O2 and probiotic metabolites on healthy cells and the detrimental effects of O2, DOX, and probiotic metabolites on cancer cells were more effective under normoxia (Figure 5E,G) than under hypoxia (Figure 5F,H). This may be attributed to the fact that O2 maintains redox hemostasis in healthy cells and the properties of metabolites are more effective when cells are metabolically active. On the other hand, under normoxia, HIF‐1α is impaired, O2 promotes DOX‐induced ROS production, probiotic metabolites interfere with the active metabolism of cancer cells and cause mitochondrial dysfunction, and thus more ROS production [81]. On the other hand, co‐application of O2, DOX and metabolites increased ROS in cancer cells at 1 day of incubation under normoxia (Figure 5E) and hypoxia (Figure 5F), while only the combination of O2/DOX (Figure 5G) and O2/metabolite (Figure 5H) showed the highest ROS in cancer cells at 7 days of incubation under normoxia and hypoxia, respectively. Co‐administration of O2, DOX, and metabolites had a moderate effect on ROS content in cancer cells at 7 days of incubation in normoxia (Figure 5G), but not in hypoxia (Figure 5H). These results indicate that, rather than directly suppressing DOX‐mediated ROS formation, probiotic metabolites modulate cellular responses to oxidative stress. The co‐presence of O2, DOX, and metabolites led to elevated ROS levels early in incubation; however, by the end of the prolonged incubation period, ROS levels in the combined system became more moderate compared to the two‐component systems, indicating that cancer cells exhibit a time‐dependent adaptation to oxidative stress. This behavior can be attributed to the effects of SCFAs, which are known to influence cellular metabolism and strengthen antioxidant defense systems; this enables cells to tolerate sustained oxidative conditions more effectively [82, 83]. Furthermore, no significant difference was observed between the group carrying DOX and the group not carrying DOX in terms of their effects on cancer cells under hypoxic conditions. This can be explained by the fact that DOX's ability to generate ROS depends on the O2 concentration. Therefore, even though our system supplied O2, the amount may not have been sufficient for DOX to exert a significant effect on cancer cells. We can analyze the results of cell viability and ROS production under hypoxia mimicking the cancer microenvironment together. In general, we observed that cell viability increased in all samples under both normoxia and hypoxia conditions when the ROS content in healthy cells decreased. However, the situation in cancer cells was different in 3D‐BioHybrid‐DOX/SPEP, which enabled co‐administration of O2, DOX, and probiotic metabolites under normoxia conditions. When % ROS in cancer cells was higher in 3D‐BioHybrid‐DOX/SPEP than in the control sample (Figure 5E,G), cancer cell viability in 3D‐BioHybrid‐DOX/SPEP was also higher than in the control sample at both 1 and 7 days of incubation under normoxia conditions (Figure 5A,C). These results may be attributed to the ability of probiotic metabolites to modulate cellular responses to oxidative stress rather than directly suppressing DOX‐mediated ROS formation. Consequently, even if ROS formation is not prevented, its impact on cellular damage can be modulated over time through enhanced cellular adaptation, which may lead to the observed increase in viability [84]. Another contradictory result was obtained in cancer cells at 7‐day incubation under hypoxia conditions. While the percentage of ROS was almost the same as the control in all samples (Figure 5H), cancer cell viability was lower than the control in all samples (Figure 5D). These results indicated that O2, DOX‐ or metabolite‐induced ROS was not the only cause of cancer cell death under these reaction conditions. O2, DOX‐, or probiotic metabolites induced cell death through other biological mechanisms even without elevating ROS. For example, O2 alleviates hypoxia and weakens cancer cell defenses [85], DOX can interfere with DNA [86], probiotic metabolites produce anti‐cancer [87] effect through metabolic pathways, all resulting in apoptosis. Conclusion In this study, multifunctional biomaterials consisting of O2‐dispersing hydrogel (GA), O2‐ and DOX‐dispersing nanomaterials in GA (GA‐DOXPMOF‐P), organosilica/polymer shell‐encapsulated probiotics (SPEP) in GA (BioHybrid‐SPEP), and the combination of all these units (BioHybrid‐DOX/SPEP) are reported. The rheological and mechanical properties of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP showed that the inclusion of SPEP decreased the complex viscosity, storage (G′) and loss modulus in the angular velocity range (G″) and mechanical (tensile stress‐strain and compressive modulus) properties of the hydrogel network, while DOXPMOF‐P improved these values of the hydrogels. This indicated that SPEP can disrupt the homogeneous interaction of GelMAF and Alg in the GA network, while the interaction between the positively charged DOXPMOF‐P and the negatively charged parts of the GA improves the mechanical and rheological properties of the GA network. The 3D printed form of these hydrogels, namely 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP, showed high cell viability and low degradation rate at 90% filler density over 7 days of incubation. The swelling properties of the hydrogels were enhanced by DOXPMOF‐P and SPEP because the hydrophilic DOXPMOF‐P and PMO‐NH2 in the structure of SPEP improved the swelling properties of the hydrogel by increasing the water holding capacity. However, the addition of SPEP increased the degradation properties of the hydrogel, while DOXPMOF‐P decreased the degradation properties of the hydrogel as observed in the mechanical properties. 3D‐GA‐DOXPMOF‐P and 3D‐BioHybrid‐DOX/SPEP showed a sustained and pH‐dependent DOX release pattern for 7 days due to intermolecular non‐covalent interactions such as hydrogen bonding between DOX and PMOF‐P. The amount and type of SCFAs released depend on time and the hydrogel used. The best results in butyric acid production were obtained in 3D‐BioHybrid‐DOX/SPEP. This can be attributed to the protective environment of the hydrogel minimizing the toxic effect of DOX on probiotics. O2‐bearing 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP showed continuous O2 delivery for 14 days, but the best result was obtained in 3D‐BioHybrid‐DOX/SPEP with the highest O2 content after 14 days of incubation due to the combination of O2‐bearing GA, DOXPMOF‐P, and SPEP in the same hydrogel network. In vitro cell experiments were performed to analyze the individual effects of O2, DOX, and probiotic metabolites and their combined effects on cell viability and ROS production. In general, O2 and metabolites reduce ROS content and improve healthy cell viability, while O2 improves probiotic metabolism and DOX activity and ROS content in cancer cells. Therefore, we obtained higher healthy cell viability than cancer cells in the majority of samples under both normoxia and hypoxia conditions. Our results predict that co‐administration of O2, DOX, and probiotic metabolites from a single hydrogel has potential in combined minimally‐invasive multi‐drug therapy applications under hypoxic conditions. It should be also noted that the observed increase in fibroblast proliferation is generally considered beneficial in the context of early tissue repair. However, the literature also emphasizes that persistent or unregulated fibroblast activation can lead to adverse outcomes, such as tissue fibrosis or the activation of cancer‐associated fibroblasts (CAFs) [88]. Therefore, in clinical practice, it is important to monitor excessive extracellular matrix accumulation or unwanted fibroblast activation to prevent potential fibrotic or tumor‐promoting effects. Experimental Section/Methods Materials Hexadecyltrimethylammonium bromide (CTAB) was obtained from Carlo Erba. Phosphate buffered saline (PBS), propionic acid, butyric acid, fetal bovine serum (FBS), trypsin‐EDTA, N‐Vinylcaprolactam (VC), L‐glutamine, cell proliferation reagent WST‐1, deuterium oxide (D2O), sodium chloride (NaCl), Paraformaldehyde (PFA), phosphoric acid, acetonitrile, Eosin Y, Griess reagent, penicillin, triethanolamine (TEA), (3‐aminopropyl)triethoxysilane (APTES), calcium chloride (CaCl2), methacrylic anhydride (MA), Agar, yeast extract, ethanol (EtOH), tryptone, lactose monohydrate, ammonia (NH3), 2′‐7′‐dichlorodihydrofluorescein diacetate (DCFH‐DA), 1,2‐bis(trimethoxysilyl)ethane (BTME), alginic acid sodium salt, powder gelatin (from porcine skin), SYTO 9 and Propidium Iodide (PI) were purchased from Sigma‐Aldrich. Hydrochloric acid (HCl) and acetic acid were obtained from Tekkim. Phenol Red Free High Glucose DMEM was purchased from Capricorn Scientific. Dulbecco's Modified Eagle Medium (DMEM) and RPMI 1640 Medium were obtained from Edukim, and Thermo Fisher Scientific, respectively. NCTC clone 929 (L cell, L‐929, derivation of Strain L) (ATCC CCL‐1) was obtained from Izmir Biomedicine and Genome Center, Türkiye. Lactobacillus casei / L. casei was obtained from the Department of Food Engineering, Izmir Institute of Technology, Türkiye. Synthesis of LacPMO‐NH2 and Lactose Release From LacPMO‐NH2 First, CTAB (485 mg) was dissolved in a mixture of EtOH (30 mL), dH2O (90 mL), and NH3 (%32, 270 µL). This solution was stirred at RT for 1 hour to complete micelle formation. Next, BTME (1.74 mL) and APTES (0.59 mL) were added to the solution for the formation of organosilica structure and modification with amine groups. The final solution was stirred at RT for 48 hours. To remove the CTAB template, EtOH (50 mL) and HCl (1.4 mL) were added to the final solution, and the final solution was heated to 50 °C while stirring for 6 hours. After that, the synthesized product (PMO‐NH2) was collected through centrifugation at 6000 rpm for 20 min, washed two times with dH2O and one time with EtOH, and dried at room temperature. Subsequently, PMO‐NH2 (100 mg) particles were suspended in dH2O (1 mL) via sonication for 15 min, and lactose monohydrate (20 mg) was dissolved in dH2O (1 mL), and they were stirred for 24 hours at room temperature. After 24 hours, the product (LacPMO‐NH2) was washed two times with dH2O and one time with EtOH by centrifugation for 20 min and LacPMO‐NH2 nanoparticles were dried at room temperature. The lactose loading capacity of PMO‐NH2 particles was quantitatively assessed via UV‐Vis spectrophotometry. A calibration curve was used to measure the amount of free lactose. The difference between the amount of lactose that was initially added and the amount of free lactose that was still present in the supernatant was used to determine how much lactose was loaded. The following formula (1) was used to calculate the lactose loading into the PMO‐NH2 pores: A series of lactose solutions with varying concentrations was prepared to establish a calibration curve. Lactose (µg/mL) release from the surface of LacPMO‐NH2 was determined in PBS (pH 6.0 and 7.4) for 7 days. LacPMO‐NH2 (1 mg) was suspended in pH 6.0 and pH 7.4 PBS (1 mL). Samples were centrifuged (6000 rpm) for 15 minutes, and supernatants were collected for each day. The absorbance of lactose was then determined by UV‐Vis spectrometry using the obtained supernatants. A calibration curve was used to quantify the amount of lactose that was released. Preparation of SPEP L. Casei were grown in lysogeny broth (LB) nutrient medium at 37 °C for 24 hours under shaking conditions at 100 rpm. Then, L. Casei was harvested by centrifugation at 2000 rpm for 5 min. The pellets were washed with sterile PBS (pH 7.4). The rinsed probiotics were resuspended in PBS, and the bacterial concentration was adjusted to approximately 1 × 105 CFU/mL using the calibration curve. For the first layer deposition, L. Casei (1 × 105 CFU/mL) was mixed with the LacPMONH2 (500 µL, 2 mg/mL) solution for 1 hour on a rotator to facilitate polycation adsorption. Thereafter, for the second layer, alginic acid sodium salt (1 mg) was added to the L. Casei coated with LacPMO‐NH2 and rotated on a rotator for 1 hour. At the last stage, LacPMO‐NH2 (500 µL, 2 mg/mL) was added to L. Casei coated with LacPMO‐NH2 and alginic acid sodium salt and rotated on a rotator for 1 hour. Coated L. Casei was collected by centrifugation at 2000 rpm for 5 min. Live/Dead Staining Test First, probiotics were coated with different concentrations of LacPMO‐NH2 (0, 0.3, 0.5, and 1 mg/mL) and incubated in PBS at 37 °C for 1 and 7 days. Thereafter, a live/dead staining test was performed using a live/dead staining kit. The mixture of SYTO9 (1 µL, 1 mg/mL) and PI (20 µL, 1 mg/mL) was prepared in PBS under dark conditions. Subsequently, 50 µL of the mixture was added to each 100 µL sample and incubated at room temperature in the dark for 15 min. Then the probiotics were examined under a microplate reader. In the second stage, probiotics / LacPMO‐NH2 were coated with different concentrations of Alg (0, 0.3, 0.5, and 1 mg/mL) and incubated in PBS at 37 °C for 1 and 7 days, and the staining process was repeated. In the last stage, probiotics/LacPMO‐NH2/Alg were coated with different concentrations of LacPMO‐NH2 (0, 0.3, 0.5, and 1 mg/mL) and incubated in PBS at 37 °C for 1 and 7 days; the live/dead staining was repeated. The live probiotics stained with SYTO 9 emit green fluorescence, while the dead probiotics stained with PI emit red fluorescence. CFU Tests for SPEP L. Casei (1 × 105 CFU/mL) was used as a negative control and treated with PBS. Then, L. Casei (1 × 105 CFU/mL) was mixed with LacPMONH2 (1 mL, 1 mg/mL) as a first layer. Second, L. Casei (1 × 105 CFU/mL) was mixed with LacPMONH2 (1 mL, 1 mg/mL) and alginic acid sodium salt (1 mg/mL), respectively. Lastly, L. Casei (1 × 105 CFU/mL) was mixed with LacPMONH2 (500 µL, 2 mg/mL), alginic acid sodium salt (1 mg/mL), and LacPMONH2 (500 µL, 2 mg/mL), respectively. All samples were incubated at 37 °C for 24 hours under shaking conditions at 100 rpm. For determining the number of viable probiotic bacteria after 24 hours, all samples were diluted in 1:10 steps down to 10−6 using M9 without glucose. Three 10 µL dots of the 100 to 10−6 dilutions for each sample were dried on agar (solid LB medium). Resulting colonies of an appropriate dilution were counted, and the average of each three dots was considered as the CFU of the respective sample. Synthesis of GelMAF Gelatin derived from bovine skin (10 g) was gradually incorporated into phosphate‐buffered saline (PBS, pH 7.4) and completely dissolved at 60°C under continuous stirring. Following full dissolution, methacrylic anhydride (8 mL) was slowly introduced into the reaction medium dropwise. The mixture was then incubated overnight at 50 °C to facilitate methacrylation. The resulting GelMA was subjected to purification through dialysis against distilled water for seven days at 37 °C, after which it was freeze‐dried. Structural characterization was performed using 1H‐NMR. To introduce O2‐carrying functionality, GelMA was chemically modified with pentadecafluorooctanoyl chloride, producing GelMAF. Initially, a 3% (w/v) GelMA solution was dissolved in acetic acid under constant stirring. Pentadecafluorooctanoyl chloride (0.14 M) was then added to the reaction mixture, which was allowed to react at ambient temperature for 24 hours. Following the reaction, the solution underwent dialysis against distilled water for three days, with frequent water replacement to ensure removal of unreacted reagents. The purified product was subsequently freeze‐dried to obtain the final GelMAF powder. The modified polymer was analyzed by 19F‐NMR. Generation of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP In order to incorporate GelMAF powder into the hydrogel scaffold, it must first be converted into a liquid form. Therefore, GelMAF stock solution was prepared with Eosin Y (0.1 mM, 648 µL), TEA (1.3% (w/v), 133 µL), and VC (1% (w/v), 0.1 g) as the photoinitiator, co‐initiator, and co‐monomer, respectively. They were mixed in PBS (10 mL, pH 7.4) at 80 °C, and then GelMAF (1 g) was slowly added to the solution. Subsequently, alginic acid sodium salt (70 mg) was added to the GelMAF stock solution (1 mL) containing cells (2 × 105 cells/mL) and mixed homogeneously to obtain particle‐free GA hydrogels. GA‐DOXPMOF‐P hydrogels were prepared by first sonicating DOXPMOF‐P (1 mg) in the GelMAF stock solution (1 mL) for 10 minutes. L929 and Malme‐3M cells (2 × 105 cells/mL) were then separately incorporated into the mixture, after which sodium alginate (70 mg) was added and mixed thoroughly to ensure homogeneity. To achieve SPEP‐incorporated hydrogels (BioHybrid‐SPEP), the coated probiotic (1 × 105 CFU/mL), GelMAF stock solution (1 mL) containing cells (2 × 105 cells/mL), and alginate (70 mg) were mixed homogeneously. Then, BioHybrid‐DOX/SPEP hydrogels were formulated by combining DOXPMOF‐P (1 mg), previously dissolved in the GelMAF stock solution via 10 minutes of sonication, with the coated probiotic (1 × 105 CFU/mL), cells (2 × 105 cells/mL), and alginate (70 mg). All hydrogels were subjected to ionic crosslinking of alginate with 0.1 M CaCl2 for 4 minutes, followed by light crosslinking of GelMAF with UV irradiation for 4 minutes at RT. Each hydrogel formulation was individually prepared for both L‐929 and Malme‐3M cell lines. Rheological and Mechanical Properties of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP Rheological characterization included viscosity‐shear rate and frequency‐dependent storage (G′) and loss (G″) moduli measurements for GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP hydrogels. The hydrogels were measured within the linear viscoelastic region using an amplitude sweep in the frequency range of 0.01–100 Hz, and the viscosity curves were obtained from rotational tests performed at shear rates ranging from 1 to 10 s−1. The hydrogels were prepared as described in Generation of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP, but for rheological analyses the samples were used in an uncrosslinked form with a final volume of 2 mL. The compressive modulus of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP hydrogels was determined using cylindrical scaffolds (5.5 mm in height and 5.5 mm in diameter), which were prepared as described in Generation of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP, lyophilized using a freeze‐dryer, and subsequently tested under a compressive load of 10 N. During the test, the samples were placed between two plates, compressed under the applied load, and the resulting deformation was recorded. The compressive modulus was then calculated from the slope of the stress–strain curve. For the tensile test, hydrogels with a thickness of 1 mm were prepared in a bone shape (17 mm × 4 mm) using a teflon mold. The samples were fixed to the grips at both ends, and tensile loads were applied at a crosshead speed of 12 mm/min until fracture occurred. The stress and strain at the point of fracture were recorded. 3D Printing of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP The 3D printing technique was employed to fabricate multifunctional 3D biomaterial scaffolds. To demonstrate the printability of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP hydrogels, hydrogels containing particles (1 mg/mL), cells (2 × 105cells/mL), and alginate (70 mg/mL) were prepared. The hydrogel mixture was mixed homogeneously with a spatula and transferred to a special syringe for 3D printing. A hexagonal structure (ca. 0.5 × 0.5 cm) was designed using printer software to be printed by the layer‐by‐layer deposition method with 90% infill density for the hydrogels. A needle with an inner diameter of 0.41 mm was used for printing, and the syringe speed was set to 80 mm/s, the injection head speed was set to 10 mm/s, and the extrusion pressure level was set to 60–100 kPa. The hydrogels were printed in a hexagonal structure and crosslinked with UV light for 2 min RT. Subsequently, ionic crosslinking with 0.1 M CaCl2 for 2 min. To prepare the scaffolds, the samples were frozen at −20°C and lyophilized using a freeze‐dryer to obtain 3D‐printed scaffolds. Swelling and Degradation Properties of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP To optimize the structural stability and degradation behavior of the printed constructs, hexagonal 3D scaffolds of BioHybrid‐DOX/SPEP were initially fabricated with three different infill densities (40%, 60%, and 90%) via bioprinting. Following fabrication, the constructs were crosslinked using a 0.1 M CaCl2 solution and UV irradiation to stabilize the hydrogel networks. The degradation behavior of the hydrogels was further assessed by measuring the weight loss over the same incubation periods. For this purpose, the pre‐weighed hydrogels (W1) were incubated under identical conditions, both in the presence and absence of fibroblast and Malme‐3M cells, and subsequently re‐weighed (W2) after 1 and 7 days. The percentage of mass loss was calculated using the Equation (2): Among the tested infill densities, the 90% infill constructs exhibited the most favorable combination of morphological integrity, dimensional accuracy, and degradation kinetics. Therefore, the 90% infill density was selected as the optimal configuration and was employed for all subsequent swelling, degradation, and biological evaluations. Then, 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP with 90% infill density were 3D‐printed and subjected to the degradation test under the same conditions. 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP were also subjected to the swelling test after 3D‐printed and cross‐linked in the same way. Each sample was subsequently weighed and immersed in 1 mL of phosphate‐buffered saline (PBS, pH 7.4) at 37 °C for incubation periods of 1 and 7 days. After incubation, samples were gently removed, blotted to remove excess PBS, and re‐weighed to determine the swelling ratio (SR) according to the following Equation (3): where W s and W d denote the swollen and initial masses of the hydrogel, respectively. Evaluation of Crosslinker Density of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP The crosslink densities of the hydrogel samples were calculated according to the Flory‐Rehner equation, as in the literature [62]. This equation Equation (4) [63] is written as: where n is the crosslink density (mol/cm3), V p is the volume fraction of the polymer in the swollen polymer, χ = 0.44 is the Huggins hydrogel‐water interaction constant, V 0 = 18 is the molar volume of water (cm3/mol). V p was calculated according to Equation (5) [64]: where D 0 = 0.997 is the density of water (g/cm3), D p = the density of hydrogel (g/cm3), and SD is the swelling degree calculated based on Equation (6) [65]. where m s is the mass of swollen hydrogel at a certain time (gram), and md is the mass of the absolute dry hydrogel (gram). The density of hydrogel (D p) was measured using the liquid displacement method Equation (7). We used a non‐solvent (ethanol) that does not swell and dissolve the hydrogel. Then we immersed dry hydrogel into ethanol and measured the displaced volume. Porosity Properties of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP Porosity (% porosity) measurements of the entire volume of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP hydrogels were performed using the ethanol replacement method. Multifunctional hydrogels were immersed in ethanol and kept overnight at room temperature. After excess ethanol was removed from the surface, the samples were weighed, and the porosity was calculated using the following equation: where M 1 and M 2 denote the masses of the scaffolds before and after immersion in ethanol, respectively; ρ represents the density of ethanol, and V is the volume of the samples Determination of DOX Release From 3D‐GA‐DOXPMOF‐P and 3D‐BioHybrid‐DOX/SPEP UV‐Vis spectrophotometry was used to quantitatively determine the released amount of DOX from 3D‐GA‐DOXPMOF‐P and 3D‐BioHybrid‐DOX/SPEP scaffolds. First, the DOX calibration curve was made by preparing different concentrations of DOX in PBS. The absorbance values at 484 nm were plotted against the DOX concentration, and the corresponding slope was determined. The relationship y = 0.0179x + 0.0684 was obtained from the plotted graph. Then, to determine the amount of DOX released from 3D‐GA‐DOXPMOF‐P and 3D‐BioHybrid‐DOX/SPEP scaffolds, these samples were immersed in 1 mL of PBS at pH 6.0 and 7.4, and then they were incubated at 37 °C for 1 day to 7 days. The PBS absorbance of the solution at specified time intervals was measured, and the released DOX amount was calculated using the equation derived from the DOX calibration curve. Furthermore, the DOX release profile from 3D‐GA‐DOXPMOF‐P and 3D‐BioHybrid‐DOX/SPEP scaffolds was fitted with Korsmeyer–Peppas and Higuchi models. CFU tests for 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP: 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP were prepared according to the procedure described in Generation of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP and BioHybrid‐DOX/SPEP. To evaluate the effects of 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP on the viability and metabolic activity of probiotics, the samples were incubated in PBS at either tumor‐mimicking conditions (pH 6.0) and physiological conditions (pH 7.4) for 1 and 7 days at 37 °C with shaking at 100 rpm. After the incubation period, the samples were transferred into glucose‐free M9 medium and further incubated for 15 min. Subsequently, the samples were serially diluted at a ratio of 1:10 up to a dilution factor of 10− 9. Three 10 µL spots from the 10− 3 to 10− 9 dilutions of each sample were dried on agar (solid LB medium). Colonies from an appropriate dilution were counted, and the mean value of the three spots was taken as the CFU of the respective sample. Determination of the O2 Carrying Capacity of 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP O2 levels in the 3D‐GelMA, 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP were measured using a fiber optic O2 sensor (OXY‐1 SMA trace, PreSens Precision Sensing GmbH). The measurements were performed under both normoxic (>21% O2) and hypoxic (<1% O2) conditions, with the hypoxic environment established using a hypoxia chamber supplied with 100% nitrogen gas. Samples were incubated for 1 and 14 days, with O2 levels monitored and recorded daily throughout the 14‐day incubation period. Determination of the Probiotic Metabolite Release Properties of 3D‐BioHybrid‐SPEP and 3D‐BioHybrid‐DOX/SPEP by HPLC First, standards of acetic acid, propionic acid, and butyric acid were prepared at different concentrations. Then, calibration curves were generated for butyric acid (R2 = 0.9987), propionic acid (R2 = 0.9988), and acetic acid (R2 = 1). The HPLC system was then filled with 100 µL of each standard solution, and the peak area of the chromatogram was plotted against the matching concentration to create calibration curves. Control (105 CFU/mL probiotic), LacPMO‐NH2‐coated probiotic, LacPMO‐NH2/Alg‐coated probiotic, SPEP, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP were prepared and incubated in dH2O (3 mL) for 1 and 7 days at 37 °C with shaking at 100 rpm. On days 1 and 7, HPLC analysis was used to quantify the amounts of acetic, butyric, and propionic acids secreted by control, LacPMO‐NH2‐coated probiotic, LacPMO‐NH2/Alg‐coated probiotic, SPEP, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP. The mobile phase consisted of 0.1% phosphoric acid (H3PO4) in water (C) and acetonitrile (D), with the following gradient elution: 0–3 min, 0% D; 3–5 min, 1% D; 5–10 min, 15% D; 10–13 min, 20% D; 13–16 min, 25% D; 16–19 min, 30% D; 19–22 min, 50% D; and 22–25 min, 0% D. Peaks were found at 210 nm after injecting 100 µL of each sample and setting the flow rate to 1.2 mL/min. The three SCFA standards were effectively separated and quantitatively identified: acetic acid (retention time = 5.35 min), propionic acid (retention time = 11.63 min), and butyric acid (retention time = 15.96 min). To evaluate the release of SCFAs from BiyoHybrid‐SPEP and BiyoHybrid‐DOX/SPEP samples, calibration curves were established for the three SCFAs. In Vitro Cell Viability Studies 3D‐printed GelMA, GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP were prepared as described in Generation of GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP and BioHybrid‐DOX/SPEP. In this study, L929 fibroblasts, a derivative of Strain L (mouse), and Malme‐3M cells derived from human malignant melanoma were utilized. These cells, at a density of 104 cells per 50 µL hydrogel, embedded within these hydrogels were incubated in 200 µL of DMEM (for fibroblast) or RPMI (for Malme‐3M) media containing 1% Penicillin, 2% L‐Glutamine, and 10% FBS. Incubations were conducted for 1 and 7 days to evaluate both short‐ and long‐term effects under normoxic (>21% O2) and hypoxic (<1% O2) conditions, maintained at 37 °C with 5% CO2. At the end of each incubation period, 3D‐GA, 3D‐GA‐DOXPMOF‐P, 3D‐BioHybrid‐SPEP, and 3D‐BioHybrid‐DOX/SPEP were washed with PBS (pH 7.4, 100 µL) and subsequently treated with WST‐1 reagent after fixation with PFA. Cell viability was assessed by measuring absorbance at 450 nm following a 4‐hour incubation under the respective O2 conditions. The results were adjusted based on the viability of the GelMA. Quantification of the ROS Fibroblast and Malme‐3M cells (104 cells per 50 µL of hydrogel) were embedded into 3D ‐GelMA, GA, GA‐DOXPMOF‐P, BioHybrid‐SPEP, and BioHybrid‐DOX/SPEP as described in In vitro cell viability studies. The samples were incubated under normoxic and hypoxic conditions at 37 °C and 5% CO2 for 1 and 7 days. At the end of each incubation period, the hydrogels were washed with PBS (pH 7.4, 100 µL), fixed with PFA, and treated with a DCFH‐DA working solution prepared in DMEM for fibroblast cells and RPMI for Malme‐3M cells. Specifically, 2.44 mg of DCFH‐DA was dissolved in 0.5 mL of the relevant medium to prepare a 10 mM stock solution, which was then diluted to 5 mL with the same medium to obtain the working solution. Each hydrogel sample was incubated with 100 µL of this working solution at 37 °C and 5% CO2 under normoxic and hypoxic conditions for 30 minutes. Following incubation, cells were washed with PBS, and the relative fluorescence intensity of the cells was measured at excitation and emission wavelengths of 485 nm and 530 nm, respectively, to quantify ROS levels. Characterization The morphology of nanoparticles, free probiotics, probiotics interacting with LacPMO‐NH2, and 3D‐printed hydrogels was assessed using scanning electron microscopy (SEM, FEI Quanta 250 FEG system; FEI, Oregon, USA). Using a Malvern Zetasizer Nano Series DLS nanoparticle size and zeta potential analyzer, zeta potential measurements and DLS analyses were carried out. Absorbance measurements were performed using a UV‐Vis spectrophotometer (UV‐2550, Shimadzu Corporation, Kyoto, Japan). High‐performance liquid chromatography (HPLC) was performed using an Agilent 1260 Infinity II device, equipped with an autosampler and a DAD detector. GL Science Inertsil ODS‐3 was used as the column, and the column temperature was adjusted to 30°C. ROS levels were measured using a microplate reader (Infinite 200 Pro, Tecan, Männedorf, Switzerland). Rheological measurements were carried out using an IC‐5332‐1732 rheometer (University of Izmir Katip Çelebi, Türkiye) equipped with a measuring system with 20 mm parallel plate, Peltier plate Steel geometry. The mechanical properties of the samples, including compression modulus and tensile stress–strain behavior, were determined using a ZwickRoell universal testing machine (model 066590). 3D‐printed hydrogel scaffolds were fabricated using a Cellink 3D bioprinter equipped with HeartWare software (version 2.4.1, CELLINK, Boston, MA, USA). Samples were lyophilized using a Labconco freeze‐dryer. Statistical Methods One‐way analysis of variance (ANOVA) in Microsoft Excel was used to statistically examine the data in order to identify group differences. Confidence intervals of 90%, 95%, and 99% were used in a one‐way ANOVA study. Statistical significance was denoted by p‐values of *p < 0.05, **p < 0.01, and ***p < 0.001, respectively. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File: mabi70233‐sup‐0001‐SuppMat.pdf. Acknowledgements We would like to thank the Scientific and Technological Research Council of Turkey (TÜBİTAK) ARDEB 1001 Grant No. 223Z039 for funding. We would like to thank Izmir Institute of Technology MAM, Environmental Development, Application and Research Center, and BIOMER Center for analytical measurements (SEM, DLS, and zeta potential), HPLC and cell culture laboratory use. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Supporting File: mabi70233‐sup‐0001‐SuppMat.pdf. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.